142 related articles for article (PubMed ID: 344288)
1. A clinical evaluation of ICRF 159 as a radiosensitising agent.
Bates T
Int J Radiat Oncol Biol Phys; 1978; 4(1-2):127-31. PubMed ID: 344288
[No Abstract] [Full Text] [Related]
2. Radiotherapy combined with ICRF 159 (NSC 129943).
Rhomberg WU
Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
[No Abstract] [Full Text] [Related]
3. Radiotherapy and ICRF 159 in the treatment of soft tissue sarcomas.
Ryall RD
Int J Radiat Oncol Biol Phys; 1978; 4(1-2):133-4. PubMed ID: 632140
[No Abstract] [Full Text] [Related]
4. Preliminary report on AT1727 as a potential radiosensitizer.
Zhang ZY; Liu TF; Zhang XF
Int J Radiat Oncol Biol Phys; 1984 Dec; 10(12):2305-7. PubMed ID: 6392223
[TBL] [Abstract][Full Text] [Related]
5. [Clinical experiences with radiotherapy and ICRF 159 in sarcomas].
Rhomberg W; Mesche E; Gefeller D; Hassenstein E
Strahlentherapie Sonderb; 1978; 75():110-4. PubMed ID: 400195
[No Abstract] [Full Text] [Related]
6. Combination of radiation and razoxane (ICRF 159) in vivo.
Hellmann K; Grimshaw MB; Hutchinson GE
Int J Radiat Oncol Biol Phys; 1978; 4(1-2):109-13. PubMed ID: 632139
[No Abstract] [Full Text] [Related]
7. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
Bakowski MT; Macdonald E; Mould RF; Cawte P; Sloggem J; Barrett A; Dalley V; Newton KA; Westbury G; James SE; Hellmann K
Int J Radiat Oncol Biol Phys; 1978; 4(1-2):115-9. PubMed ID: 344287
[No Abstract] [Full Text] [Related]
8. Radiation as a therapeutic modality in sarcomas of the soft tissue.
Suit H; Spiro I
Hematol Oncol Clin North Am; 1995 Aug; 9(4):733-46. PubMed ID: 7490238
[TBL] [Abstract][Full Text] [Related]
9. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
Bakowski MT
Cancer Treat Rev; 1976 Jun; 3(2):95-107. PubMed ID: 821609
[No Abstract] [Full Text] [Related]
10. ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
Kovacs CJ; Evans MJ; Schenken LL; Burholt DR
Br J Cancer; 1979 May; 39(5):516-23. PubMed ID: 486307
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study.
Rhomberg W; Hassenstein EO; Gefeller D
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1077-84. PubMed ID: 8985029
[TBL] [Abstract][Full Text] [Related]
12. Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours.
Thomlinson RH; Dische S; Gray AJ; Errington LM
Clin Radiol; 1976 Apr; 27(2):167-74. PubMed ID: 776494
[TBL] [Abstract][Full Text] [Related]
13. ICRF-159: current status and clinical prospects.
Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
[No Abstract] [Full Text] [Related]
14. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
Hellmann K; Ryall RD; Macdonald E; Newton KA; James SE; Jones S
Cancer; 1978 Jan; 41(1):100-7. PubMed ID: 414829
[TBL] [Abstract][Full Text] [Related]
15. [Combined treatment of lung carcinoma. Report on a prospective randomized study with radiotherapy and ICRF 159 (1,2-(3,5-dioxopiperazines-lyl)propane) (author's transl)].
Hassenstein E; Rhomberg W
Med Klin; 1977 Feb; 72(5):171-5. PubMed ID: 403395
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159.
Ryall RD; Hanham IW; Newton KA; Hellmann K; Brinkley DM; Hjertaas OK
Cancer; 1974 Oct; 34(4):1040-5. PubMed ID: 4608365
[No Abstract] [Full Text] [Related]
17. ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
Kovacs CJ; Evans MJ; Burholt DR; Schenken LL
Br J Cancer; 1979 May; 39(5):524-30. PubMed ID: 486308
[TBL] [Abstract][Full Text] [Related]
18. A small prospective study of chordomas treated with radiotherapy and razoxane.
Rhomberg W; Böhler FK; Novak H; Dertinger S; Breitfellner G
Strahlenther Onkol; 2003 Apr; 179(4):249-53. PubMed ID: 12707714
[TBL] [Abstract][Full Text] [Related]
19. Reduced survival with radiotherapy and razoxane compared with radiotherapy alone for inoperable lung cancer in a randomised double-blind trial.
Newman CE; Cox R; Ford CH; Johnson JR; Jones DR; Wheaton M
Br J Cancer; 1985 May; 51(5):731-2. PubMed ID: 3888243
[No Abstract] [Full Text] [Related]
20. Phase II study of ICRF-159 in refractory metastatic breast cancer.
Creech RH; Engstrom PF; Harris DT; Catalano RB; Bellet RE
Cancer Treat Rep; 1979 Jan; 63(1):111-4. PubMed ID: 369681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
